The Parker Institute sponsors several immunotherapeutic clinical trials. These are the PICI trials currently open for accrual at MSKCC.
- PICI0001
A Phase II Study of Immunotherapy: Ipilimumab Alone or with Nivolumab in Patients Whose Melanoma Continues to Grow Despite Nivolumab or Pembrolizumab - PICI0002
A Phase IB/II Study of APX005M Immunotherapy plus Gemcitabine and nab-Paclitaxel, with or without Nivolumab, in Patients with Previously Untreated Metastatic Pancreatic Cancer